Chimeric antigen receptor (CAR)-T cell therapy faces a critical clinical hurdle: cytokine release syndrome (CRS). Current CRS management strategies have limited selectivity and may interfere with CAR-T cell antitumor activity, highlighting the need for more targeted and precisely controllable interventions. Nanoenginee...
Rui-Song Li, Nan Li, Tian-Yu Luo et al.· Journal of Controlled Releas...· 0 citations
The latest research, mechanisms, and applications of CAR-T cell therapy in non-oncological diseases, the pathogenesis of related disorders, and the advantages, challenges, and future prospects of CAR-T cell therapy are introduced.
Zhuo-Lin Fan, Xu Zheng, C. Jin et al.· Signal Transduction and Targ...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.